Format

Send to

Choose Destination
Nat Rev Microbiol. 2008 May;6(5):349-62. doi: 10.1038/nrmicro1840.

Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.

Author information

1
Host-Microbe Interactomics, University of Wageningen, Animal Sciences Department, P.O. BOX 338, 6700 AH, Wageningen, The Netherlands. jerry.wells@wur.nl

Abstract

Studies of lactic acid bacteria (LAB) as delivery vehicles have focused mainly on the development of mucosal vaccines, with much effort being devoted to the generation of genetic tools for antigen expression in different bacterial locations. Subsequently, interleukins have been co-expressed with antigens in LAB to enhance the immune response that is raised against the antigen. LAB have also been used as a delivery system for a range of molecules that have different applications, including anti-infectives, therapies for allergic diseases and therapies for gastrointestinal diseases. Now that the first human trial with a Lactococcus strain that expresses recombinant interleukin-10 has been completed, we discuss what we have learnt, what we do not yet understand and what the future holds for therapy and prophylaxis with LAB.

PMID:
18345021
PMCID:
PMC7096801
DOI:
10.1038/nrmicro1840
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center